VISIONARY: A Phase 3 clinical trial of sibeprenlimab for adults with IgA Nephropathy. Targeting a brighter future for IgAN patients.
IgAN, sometimes called “Berger’s Disease”, is a rare condition. Until now, many treatment options only focus on relieving or managing symptoms. The VISIONARY Study is researching an investigational drug which aims to target the root cause of IgAN.
Now Enrolling – To find out more information on the trial, visit our website at visionarystudy.com